tirzepatide versus semaglutide once weekly vs Tirzepatide: Which GLP-1 Wins for Weight Loss? tirzepatide versus semaglutide once weekly

Ertugliflozin The Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial (VERTIS CV) was a multicentre RCT in which 8246 patients with T2D and atherosclerotic cardiovascular disease were randomized to receive either 5 mg or 15 mg of ERTU versus placebo once a day

Unlike traditional insulin therapy, which directly supplements insulin levels, GLP-1 receptor agonists like semaglutide enhance the bodys natural secretion of insulin in response to increased blood glucose levels

Researchers who have experience with semaglutide dosing or tirzepatide dosing sometimes assume that retatrutide titration can be more aggressive because of their prior experience with GLP-1 receptor activation

While 15 mg is the maximum weekly dose, best depends on your balance of results and tolerability

doi: 10.1002/oby.23673, 159 WildingJ

[14] Cheng, J.-R., Zheng, J., Li, Y., Shi, H., Yang, N., Lei, Y., Wan, Y.-F